CTNM
Contineum Therapeutics, Inc. Class A Common StockHealthcare·Biotechnology
$13.49
$504M market cap
Revenue
$0.0M
Free Cash Flow
$-29.7M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small m
2-Year Price History
$13.86-9.5%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -16.9 | -16.9 | -14.5 | -16.3 | -16.6 | -0.3 | 246.3 | 7.0 | 37.3 | -85.0% | -- | -- |
| Act | 2025-Q4 | 0.0 | -17.0 | -17.1 | -15.2 | -13.0 | -13.1 | -0.0 | 262.9 | 8.3 | 30.9 | -73.6% | -- | -- |
Valuation & Metrics
Market Stats
Price$13.49
Market Cap$504M
Enterprise Value$265M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-5.9%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-29.6M
Free Cash Flow$-29.7M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-79.3%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.6M
Days to Cover6.7
Change (vs Prior)-48.2%
Need at least 2 settlement dates for chart
Employees
Headcount41
Revenue / Employee$0
Gross Profit / Employee$0
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
67.2%(+49.6% YoY)
79 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
6.2%(+3.9% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
1.2%(+1.2% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $37.1M | $15.43 | +$0 | +$14.6M | -9.0% | $3.69B |
| JANUS HENDERSON GROUP PLC | $35.6M | $11.68 | +$3.7M | +$35.0M | +1.2% | $209.29B |
| JOHNSON & JOHNSON | $25.8M | $17.61 | +$0 | +$0 | -6.8% | $652M |
| FRANKLIN RESOURCES INC | $24.0M | $15.95 | −$524K | +$3.4M | -0.2% | $403.03B |
| BALYASNY ASSET MANAGEMENT LLC | $22.0M | $11.60 | −$2.1M | +$22.0M | -0.4% | $48.01B |
| MILLENNIUM MANAGEMENT LLC | $20.1M | $11.64 | +$9.2M | +$20.1M | -0.5% | $127.40B |
| BAKER BROS. ADVISORS LP | $18.6M | $12.60 | +$0 | +$14.5M | -0.4% | $16.13B |
| RA CAPITAL MANAGEMENT, L.P. | $16.9M | $11.74 | −$11.5M | +$16.9M | -4.4% | $9.44B |
| PERCEPTIVE ADVISORS LLC | $16.4M | $15.58 | −$2.7M | −$2.4M | -1.3% | $5.05B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $15.9M | $13.06 | +$15.9M | +$15.9M | — | $4.04T |
| FMR LLC | $10.6M | $16.27 | +$0 | +$59K | -0.0% | $1.89T |
| Ikarian Capital, LLC | $10.6M | $12.49 | +$6.9M | +$10.6M | -8.8% | $698M |
| GREAT POINT PARTNERS LLC | $10.5M | $11.43 | +$3K | +$10.5M | -4.5% | $408M |
| Longaeva Partners L.P. | $9.6M | $12.01 | +$3.4M | +$9.6M | -0.5% | $2.08B |
| SECTORAL ASSET MANAGEMENT INC | $9.5M | $17.61 | −$956K | −$956K | -0.5% | $117M |
| HHLR ADVISORS, LTD. | $8.7M | $17.61 | +$0 | +$0 | -1.5% | $1.67B |
| BlackRock, Inc.Passive | $8.7M | $14.97 | +$1.7M | +$686K | -0.2% | $5.69T |
| Red Tree Management, LLC | $8.3M | $14.65 | +$0 | +$0 | -3.9% | $112M |
| Versant Venture Management, LLC | $7.1M | $17.61 | +$0 | −$4.9M | -13.9% | $141M |
| Jones Hill Capital LP | $6.7M | $13.06 | +$6.7M | +$6.7M | — | $466M |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-2.14%
avg per quarter
Holders (ex-self)
-2.10%
excl. this stock
Buyers (this Q)
-0.87%
50 buyers · $0.09B in
Sellers (this Q)
-2.43%
22 sellers · $0.01B out
alpha coverage: 94% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+8.7%
how holders react when this stock falls
On quiet Qs
+6.8%
−10% to +10% baseline
On rallies (+10%+)
+26.0%
how they react when this stock rises
Holders' portfolio flow this Q
+3.5%
inflows — adds are organic
Sellers' portfolio flow this Q
-7.9%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-8.4%
Holder mid (any stock)
-4.7%
Holder rally (any stock)
-9.6%
Biggest decreases this quarter
RA CAPITAL MANAGEMENT, L.P.−$11.5Mα-4.4Commodore Capital LPexited−$9.3MPERCEPTIVE ADVISORS LLC−$2.7Mα-1.3AMERIPRISE FINANCIAL INCexited−$2.4MBALYASNY ASSET MANAGEMENT LLC−$2.1Mα-0.4Monashee Investment Management LLCexited−$1.6MSECTORAL ASSET MANAGEMENT INC−$956Kα-0.5Samsara BioCapital, LLCexited−$826KFRANKLIN RESOURCES INC−$524Kα-0.2Schonfeld Strategic Advisors LLCexited−$259K
New buyers this quarter
Top-5 holders · 36.2%
SUVRETTA CAPITAL MANAGEMENT, LLC--
JANUS HENDERSON GROUP PLC--
JOHNSON & JOHNSON--
FRANKLIN RESOURCES INC--
BALYASNY ASSET MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
JOHNSON & JOHNSON2.0MSUVRETTA CAPITAL MANAGEMENT, LLC2.8MJANUS HENDERSON GROUP PLC2.7MPERCEPTIVE ADVISORS LLC1.3MRA CAPITAL MANAGEMENT, L.P.1.3MFRANKLIN RESOURCES INC1.8MBALYASNY ASSET MANAGEMENT LLC1.7MMILLENNIUM MANAGEMENT LLC1.5MBAKER BROS. ADVISORS LP1.4MVersant Venture Management, LLC543K
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$16.001860.0%
Last Year (5 analysts)$17.202750.0%
Current Price$13.49
Analyst Ratings
2
1
Buy: 2Hold: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$737K
16 txns · 3 insiders · 51,977 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-01 | SELL | Lorrain Daniel S. | officer: Chief Scientific Officer | 4,170 | $13.12 | $55K | $1.88M |
| 2026-04-06 | SELL | Lorrain Daniel S. | officer: Chief Scientific Officer | 4,170 | $13.43 | $56K | $1.98M |
| 2026-03-02 | SELL | Lorrain Daniel S. | officer: Chief Scientific Officer | 4,170 | $15.01 | $63K | $2.28M |
| 2026-03-02 | SELL | Watkins Tim | officer: CMO & Head of Development | 3,611 | $15.02 | $54K | $0 |
| 2026-02-25 | SELL | Lorrain Daniel S. | officer: Chief Scientific Officer | 3,824 | $16.01 | $61K | $2.50M |
| 2026-02-25 | SELL | Stengone Carmine N. | director, officer: CEO and President | 2,700 | $16.02 | $43K | $239K |
| 2026-02-24 | SELL | Lorrain Daniel S. | officer: Chief Scientific Officer | 4,300 | $16.03 | $69K | $2.50M |
| 2026-02-24 | SELL | Stengone Carmine N. | director, officer: CEO and President | 4,400 | $16.02 | $70K | $240K |
| 2026-02-19 | SELL | Lorrain Daniel S. | officer: Chief Scientific Officer | 100 | $16.00 | $2K | $2.50M |
| 2026-02-11 | SELL | Lorrain Daniel S. | officer: Chief Scientific Officer | 400 | $16.00 | $6K | $2.50M |
| 2026-02-11 | SELL | Stengone Carmine N. | director, officer: CEO and President | 400 | $16.00 | $6K | $239K |
| 2026-02-03 | SELL | Lorrain Daniel S. | officer: Chief Scientific Officer | 4,170 | $14.94 | $62K | $2.33M |
| 2026-01-28 | SELL | Watkins Tim | officer: CMO & Head of Development | 3,611 | $14.18 | $51K | $0 |
| 2026-01-05 | SELL | Lorrain Daniel S. | officer: Chief Scientific Officer | 4,170 | $10.44 | $44K | $1.67M |
| 2025-12-29 | SELL | Watkins Tim | officer: CMO & Head of Development | 3,611 | $12.06 | $44K | $0 |
| 2025-12-23 | SELL | Lorrain Daniel S. | officer: Chief Scientific Officer | 4,170 | $12.23 | $51K | $2.01M |
Order Flow (FINRA, ~3w lag)
34.5%retail-2.2pp
14.6%dark-9.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Contineum Therapeutics: The Dilution Engine Powered by Constrained Milestones
Overall Risk
5/10
Fraud
2/10
Dilution
9/10
Insolvency
2/10
Earnings Overstated
1/10
Hidden Liabilities
3/10
Legal
2/10
Audit Warnings
3/10
Hidden Upside
8/10
Contextually Acceptable
8/10